Gate Square “Creator Certification Incentive Program” — Recruiting Outstanding Creators!
Join now, share quality content, and compete for over $10,000 in monthly rewards.
How to Apply:
1️⃣ Open the App → Tap [Square] at the bottom → Click your [avatar] in the top right.
2️⃣ Tap [Get Certified], submit your application, and wait for approval.
Apply Now: https://www.gate.com/questionnaire/7159
Token rewards, exclusive Gate merch, and traffic exposure await you!
Details: https://www.gate.com/announcements/article/47889
VB vs ISCB: Which Small-Cap Play Deserves Your Money?
The Setup
When hunting for small cap exposure through ETFs, two heavyweights keep coming up: Vanguard’s VB and iShares’ ISCB. On the surface, they seem almost interchangeable—both chase diversified U.S. small-cap returns, both keep fees razor-thin, both hold a sprawling collection of mid-sized companies. But dig deeper, and you’ll find meaningful differences in how they’re constructed, how they trade, and—most importantly—how they’ve actually performed.
The fundamental split: VB tracks the CRSP U.S. Small Cap Index (basically a broad market capture of eligible small companies), while ISCB builds its portfolio using Morningstar’s proprietary quantitative scoring system. That distinction matters more than you’d think.
Cost: A Photo Finish
Let’s start with the friction—expense ratios. ISCB comes in at 0.04%, while VB sits at 0.05%. The spread is minuscule (we’re talking single basis points), but in a world of fee wars, ISCB technically claims the crown.
However, here’s where things get interesting: ISCB pulls in just $257.4 million in assets under management, while VB commands a staggering $163.3 billion. That scale difference translates directly into trading dynamics you’ll actually feel as an investor.
Inside the Portfolios
ISCB holds roughly 1,540 stocks, weighted across industrials (19%), technology (16%), and financial services (15%). Its top holdings—Ciena, Coherent, Rocket Lab—each represent less than 0.6% of the fund. The portfolio leans slightly heavier on financials than its competitor.
VB manages about 1,357 stocks with a marginally different flavor: industrials lead at 20%, followed by tech at 18%, with a lighter financial services tilt. Major positions like Insmed and Comfort Systems USA stay below 0.7% of assets.
Both funds spread risk aggressively across sectors, but ISCB’s broader holding count provides slightly more granular diversification.
The Performance Question
Here’s where it gets spicy. Over the trailing 12 months (as of December 2025), ISCB delivered 14.3% returns versus VB’s 10.5%. ISCB won this round handily.
But rewind the tape: over 5 years, VB’s $1,000 investment grew to $1,493, while ISCB’s reached $1,480. VB pulled ahead. Extend that to 10 and 20 years? VB dominates, compounding at 9.6% annually versus ISCB’s 8.5%.
The catch: ISCB showed a maximum drawdown of (29.94%) over 5 years, slightly deeper than VB’s (28.15%). Both funds move similarly to broader markets (betas around 1.23-1.27), but over multi-year stretches, VB’s long-established track record—it’s been running since 2004—has consistently paid off.
The Liquidity Factor
This often gets overlooked but shouldn’t. VB’s $163 billion in assets means you can trade in size without moving the needle on pricing. It’s a darling among institutional investors. ISCB, by contrast, operates as a far smaller pond—$257.4 million is respectable but leaves you with wider bid-ask spreads on larger trades.
For retail investors buying and holding, it’s a non-issue. For anyone actively trading positions, VB’s deep liquidity is a tangible advantage.
The Verdict
Both are legitimately excellent small-cap ETF options, especially for investors looking to dial back exposure to the “Magnificent Seven” and mega-cap tech dominance that’s defined the last decade’s returns.
That said, if forced to choose, VB edges ISCB. The reasons are straightforward: superior long-term performance (that 1.1% annual outperformance compounds), vastly superior trading liquidity, and a two-decade head start in proving its index-tracking discipline. ISCB’s edge on expenses and its broader portfolio hold appeal, but they don’t outweigh VB’s structural advantages.
The real takeaway? You won’t regret either pick. Both keep costs buried, both deliver diversified small-cap exposure, and both let you sidestep concentration risk from mega-cap darlings. Your choice ultimately depends on position size and whether you value VB’s scale and track record or ISCB’s marginally broader holdings and lower fee.